Blackrock Neurotech is the leading provider of implantable brain-computer interface (BCI) technology, headquartered in Salt Lake City, Utah. Founded in 2008 as a spinout from the University of Utah, the company has developed the most clinically validated invasive BCI technology in the world through its flagship Utah Array.
The company holds a unique position as the only provider of FDA-approved implantable neural arrays, with over 15 years of continuous clinical data from more than 50 patient implantations. This regulatory moat, combined with an extensive patent portfolio and established manufacturing capabilities, has made Blackrock the dominant player in the clinical-grade invasive BCI market.
Blackrock raised over $120 million in total funding before transitioning to commercial stage with its FDA-approved MoveAgain BCI system in 2023. The company employs approximately 150 people and is pursuing an aggressive product roadmap including next-generation Neuralace technology with 10,000+ electrodes.
| Attribute | Details |
|---|---|
| Founded | 2008 |
| Headquarters | Salt Lake City, Utah |
| CEO | Marcus Gerhardt |
| Total Funding | $120M+ |
| Employees | ~150 |
| FDA Approvals | 2 (Utah Array, MoveAgain BCI) |
| Clinical Patients | 50+ |
| Market Share | ~70% (invasive BCI) |
The Utah Array is Blackrock's flagship product and the gold standard for chronic neural interface technology:
The MoveAgain BCI received FDA approval in 2023 as the first commercial BCI system for patients with paralysis:
Next-generation ultra-high-density array:
Blackrock competes with Neuralink, Synchron, and Paradromics in the invasive BCI space. Key differentiators include:
Blackrock is targeting:
The global BCI market is projected to reach $7B by 2030, with invasive BCI representing approximately $1.5B.